{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "BARI-OPTIMISE: A Randomised Controlled Trial"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This double-blind, randomised, placebo-controlled trial involved 70 adults"
      },
      "Participants": {
        "score": 2,
        "evidence": "70 adults with \u226420% weight loss post-RYGB or SG and suboptimal GLP-1 response, recruited from two London hospitals"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised 1:1 to liraglutide, 3.0 mg, or placebo"
      },
      "Objective": {
        "score": 1,
        "evidence": "This trial assesses liraglutide, 3.0 mg, for weight reduction in patients with poor weight loss and suboptimal GLP-1 response post-surgery."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was percentage body weight change from baseline to 24 weeks"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, stratified by surgery type and diabetes status, with allocation concealed."
      },
      "Blinding": {
        "score": 3,
        "evidence": "All participants and study personnel were blinded."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "70 adults with \u226420% weight loss post-RYGB or SG and suboptimal GLP-1 response, recruited from two London hospitals between October 2018 and November 2019."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Of 70 randomised (35 per group), 57 completed follow-up."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Mean percentage weight change was \u22128.82% (SD 4.94) with liraglutide vs \u22120.54% (SD 3.32) with placebo. The mean difference was \u22128.03% (95% CI, \u221210.39 to \u22125.66; P < 0.001)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were more frequent with liraglutide (80%) than placebo (57%), predominantly gastrointestinal, with no serious events or deaths."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "ClinicalTrials.gov Identifier: NCT03341429"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 24,
    "max_score": 25
  },
  "model": "gpt-4o"
}